A systematic review of hypofractionation for primary management of prostate cancer

European Urology

Volumn 68, Issue 4, 2015, Pages 683-691

  Koontz, Bridget F ^a   Bossi, Alberto ^b   Cozzarini, Cesare ^c   Wiegel, Thomas ^d   D'Amico, Anthony ^e  

^a DUKE CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gastrointestinal toxicity; Genitourinary toxicity; Hypofractionation; Prostate cancer; Prostate specific antigen; Randomized trials; Stereotactic radiation therapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; EXTREME HYPOFRACTIONATION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOW RISK PATIENT; MODERATE HYPOFRACTIONATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; TREATMENT PLANNING; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; BRACHYTHERAPY; HYPOFRACTIONATED RADIOTHERAPY; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RISK FACTOR; TREATMENT OUTCOME;

BRACHYTHERAPY; DOSE HYPOFRACTIONATION; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84941775271     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.009     Document Type: Review

References (50)

1. D. Eriksson, and T. Stigbrand Radiation-induced cell death mechanisms Tumour Biol 31 2010 363 372
2. D.P. Dearnaley, M.R. Sydes, J.D. Graham, and et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
3. A. Dasu, and I. Toma-Dasu Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients Acta Oncol 51 2012 963 974
4. M. Ritter Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer Sem Radiat Oncol 18 2008 249 256
5. J.C. Hodges, T. Boike, Y. Lotan, and et al. Cost effectiveness analysis of stereotactic body radiation therapy (SBRT) versus intensity modulated radiation therapy (IMRT) for low or intermediate risk prostate cancer: a Markov model decision analysis Int J Radiat Oncol Biol Phys 81 2011 S560
6. D.J. Sher, R. Parikh, S. Mays-Jackson, and R.S. Punglia Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer Am J Clin Oncol 37 2014 215 221
7. H.D. Skinner, K.E. Hoffman, L.B. Levy, and et al. Toxicity and dosimetric parameters related to conventional versus dose-escalated, hypofractionated radiation in prostate cancer Int J Radiat Oncol Biol Phys 84 2012 S147
8. American College of Radiology (ACR) ACR-ASTRO practice guideline for the performance of stereotactic body radiation therapy 2009 ACR Reston, VA
9. S. Aubin, L. Beaulieu, S. Pouliot, and et al. Robustness and precision of an automatic marker detection algorithm for online prostate daily targeting using a standard V-EPID Med Phys 30 2003 1825 1832
10. M.M. Quigley, T.P. Mate, and J.E. Sylvester Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses Urol Oncol 27 2009 473 482
11. S. Both, K.K. Wang, J.P. Plastaras, and et al. Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon Int J Radiat Oncol Biol Phys 8 2011 1302 1309
12. G. Arcangeli, B. Saracino, S. Gomellini, and et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 78 2010 11 18
13. S. Arcangeli, L. Strigari, S. Gomellini, and et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 84 2012 1172 1178
14. D.A. Kuban, G.M. Nogueras-Gonzalez, L. Hamblin, and et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation Int J Radiat Oncol Biol Phys 78 2010 S58 S59
15. H. Lukka, C. Hayter, J.A. Julian, and et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
16. A. Pollack, G. Walker, E.M. Horwitz, and et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer J Clin Oncol 31 2013 3860 3868
17. E.E. Yeoh, R.J. Botten, J. Butters, A.C. Di Matteo, R.H. Holloway, and J. Fowler Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial Int J Radiat Oncol Biol Phys 81 2011 1271 1278
18. D. Dearnaley, I. Syndikus, G. Sumo, and et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial Lancet Oncol 13 2012 43 54
19. K.E. Hoffman, K.R. Voong, T.J. Pugh, and et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial Int J Radiat Oncol Biol Phys 88 2014 1074 1084
20. S. Arcangeli, L. Strigari, S. Gomellini, and et al. Updated results and pattern of failure in a randomized hypofractionation trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 84 2012 S147
21. A.W. Pederson, J. Fricano, D. Correa, C.A. Pelizzari, and S.L. Liauw Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity Int J Radiat Oncol Biol Phys 82 2012 235 241
22. B.A. Jereczek-Fossa, L. Santoro, D. Zerini, and et al. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients J Urol 189 2013 2099 2103
23. P. Jean-Pierre, R. Stoyanova, F. Penedo, and et al. Treatment-related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase III hypofractionation trial Int J Radiat Oncol Biol Phys 81 2011 S667
24. A. Katz, and J. Kang Stereotactic body radiation therapy for low-, intermediate-, and high-risk prostate cancer: disease control and quality of life at 6 years Int J Radiat Oncol Biol Phys 87 2013 S24 S25
25. A. Loblaw, P. Cheung, L. D'Alimonte, and et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes Radiother Oncol 107 2013 153 158
26. Z.A. Alicikus, Y. Yamada, Z. Zhang, and et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer Cancer 117 2011 1429 1437
27. G. Bolzicco, M.S. Favretto, N. Satariano, E. Scremin, C. Tambone, and A. Tasca A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy BMC Urol 13 2013 49
28. T.P. Boike, Y. Lotan, L.C. Cho, and et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 29 2011 2020 2026
29. C. Menkarios, T. Vigneault, N. Brochet, and et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial Radiat Oncol 6 2011 112
30. L.N. Chen, S. Suy, H. Wang, and et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer Radiat Oncol 9 2014 148
31. C. Oliai, R. Lanciano, B. Sprandio, and et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer J Radiat Oncol 2 2013 63 70
32. A.W. Ju, H. Wang, E.K. Oermann, and et al. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer Radiat Oncol 8 2013 30
33. J.B. Yu, L.D. Cramer, J. Herrin, P.R. Soulos, A.L. Potosky, and C.P. Gross Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity J Clin Oncol 32 2014 1195 1201
34. C.R. King, J.D. Brooks, H. Gill, and J.C. Presti Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 877 882
35. D.W. Kim, L.C. Cho, C. Straka, and et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 89 2014 509 517
36. D. Kim, C. Straka, L. Cho, and et al. Predictors of high-grade rectal toxicity observed in a phase 1/2 trial of stereotactic body radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 87 2013 S358 S359
37. O. Bhattasali, L.N. Chen, J. Woo, and et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer Radiat Oncol 9 2014 52
38. R. Meier, I. Kaplan, A. Beckman, and et al. Patient-reported quality of life outcomes in intermediate-risk prostate cancer patients treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 87 2013 S25
39. D.B. Fuller, G. Mardirossian, D. Wong, and et al. Prospective evaluation of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer: emulating high-doserate brachytherapy dose distribution Int J Radiat Oncol Biol Phys 84 2012 S149
40. J.L. Friedland, D.E. Freeman, M.E. Masterson-McGary, and D.M. Spellberg Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer Technol Cancer Res Treat 8 2009 387 392
41. T.M. Pisansky, S.L. Pugh, R.E. Greenberg, and et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial JAMA 311 2014 1300 1307
42. J.B. Adkison, D.R. McHaffie, S.M. Bentzen, and et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 184 190
43. S. Drodge, N. Pervez, S. Ghosh, and et al. Late toxicity in high-risk prostate cancer treated with androgen suppression and hypofractionated intensity modulated radiotherapy Int J Radiat Oncol Biol Phys 78 2010 S353
44. H. Quon, P.C. Cheung, D.A. Loblaw, and et al. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity Int J Radiat Oncol Biol Phys 82 2012 898 905
45. P.J. Hoskin, A.M. Rojas, P.J. Bownes, G.J. Lowe, P.J. Ostler, and L. Bryant Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer Radiother Oncol 103 2012 217 222
46. S. Aluwini, G. Beltramo, P. Van Rooij, J. Boormans, W. Kirkels, and I.K. Kolkman-Deurloo Stereotactic body radiotherapy with four fractions for low- and intermediate-risk prostate cancer: acute and late toxicity Eur Urol Suppl 12 2013 156
47. L.N. Chen, S. Suy, S. Uhm, and et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience Radiat Oncol 8 2013 58
48. L. D'Alimonte, A. Loblaw, P. Cheung, and et al. Long term outcomes of a novel five fraction hypofractionated protocol for low risk prostate cancer J Med Imaging Radiat Sci 44 2013 47
49. R. Meier, I. Kaplan, A. Beckman, and et al. Stereotactic body radiation therapy for intermediate-risk organ confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study Int J Radiat Oncol Biol Phys 84 2012 S148
50. H. Ouon, P. Cheung, A. Cesta, and et al. Prospective study of extreme hypofractionated radiotherapy (35GY in five fractions) for low-risk prostate cancer: toxicity results Radiother Oncol 96 2010 S46